Prognostic factors in ductal pancreatic cancer

Langenbecks Arch Surg. 1998 Apr;383(2):129-33. doi: 10.1007/s004230050104.


Introduction: The diagnosis of pancreatic adenocarcinoma remains a devastating life event for most patients and their families. Many patients with this relatively common malignancy present at a stage of disease not amenable to cancer-directed resectional therapy, and are treated via nonoperative palliative measures, with median survival of 4-8 months post-diagnosis.

Conclusion: A minority of patients present with disease limited to the pancreas and periampullary region and are candidates for resectional therapy. The prognosis for these patients is determined by several factors: clinicopathologic staging, tumor biology and molecular genetics, perioperative factors and the use of postoperative adjuvant therapy.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / mortality
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy
  • Combined Modality Therapy
  • Humans
  • Lymphatic Metastasis
  • Neoplasm Staging
  • Palliative Care
  • Pancreatic Ducts* / pathology
  • Pancreatic Neoplasms / diagnosis*
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / therapy
  • Prognosis
  • Survival Rate